Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 7:03 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1249–1272 of 1,585 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Diabetes Mellitus, Juvenile-Onset Clear all

Conditions: Type 1 Diabetes Mellitus
Interventions: Not listed
Lead sponsor: Children's Mercy Hospital Kansas City; Other
Eligibility: 7 Years to 14 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Diabetes, Diabetes Mellitus, Type 1
Interventions: insulin degludec, insulin glargine; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Type 1 Diabetes Mellitus
Interventions: Group education sessions; Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 13 Years to 18 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Type 1 Diabetes Mellitus
Interventions: Placebo, Sotagliflozin; Drug
Lead sponsor: Lexicon Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 793 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 63
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Escondido, California + 55 more

Conditions: Diabetes Mellitus, Type 1, Pregnancy in Diabetics, Pregnancy, High-Risk, Insulin Dependent Diabetes
Interventions: Hybrid closed loop insulin delivery system; Device
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 18 Years and older · Female only
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 10
States / cities: Birmingham, Alabama • Aurora, Colorado • Tampa, Florida + 6 more

Conditions: Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Delivery Systems
Interventions: NovoFine® needle 6 mm, Ultra-Fine needle 12.7 mm; Device
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 5
States / cities: Walnut Creek, California • Berlin, New Jersey • Lawrenceville, New Jersey + 2 more

Conditions: Diabetic Macular Edema
Interventions: Aliskiren, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 10
States / cities: Phoenix, Arizona • Los Angeles, California • Fort Myers, Florida + 7 more

Conditions: Type 1 Diabetes Mellitus
Interventions: Closed Loop; Device
Lead sponsor: Medtronic MiniMed, Inc.; Industry
Eligibility: 12 Years to 30 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Diabetes Mellitus, Type 1
Interventions: Internet co-management module; Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 39 Years
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Type 1 Diabetes, Type 2 Diabetes
Interventions: Not listed
Lead sponsor: VeraLight, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Hyattsville, Maryland

Conditions: Diabetes Mellitus, Type 1
Interventions: Medtronic 670G; Device
Lead sponsor: Stanford University; Other
Eligibility: 7 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Stanford, California

Conditions: Type 1 Diabetes
Interventions: Simple Meal Bolusing, Carbohydrate counting; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 14 Years to 26 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Type 1 Diabetes
Interventions: High fat meal; Other
Lead sponsor: Joslin Diabetes Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Type 1 Diabetes Mellitus
Interventions: Teplizumab, Placebo; Biological · Drug
Lead sponsor: MacroGenics; Industry
Eligibility: 8 Years to 35 Years
Enrollment: 554 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 39
States / cities: Birmingham, Alabama • Jonesboro, Arkansas • Little Rock, Arkansas + 36 more

Conditions: Type 1 Diabetes
Interventions: Empagliflozin + Control-IQ x 4 wks then Basal-IQ x 2 wks, Empagliflozin + Basal-IQ x 2 wks then Control-IQ x 4 wks, No Empagliflozin + Control-IQ x 4 wks then Basal-IQ x 2 wks, No Empagliflozin + Basal-IQ x 2 wks then Control-IQ x 4 wks; Combination Product · Device
Lead sponsor: Ananda Basu, MD; Other
Eligibility: 18 Years to 65 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Type 1 Diabetes
Interventions: SMA visits; Behavioral
Lead sponsor: Children's National Research Institute; Other
Eligibility: 8 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Leukemia, T-Cell, Lymphoma, T-Cell, Cutaneous
Interventions: Yttrium-90 radiolabeled anti-Tac antibody; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1989 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Diabetes Mellitus, Insulin-Dependent
Interventions: hokt3g1 (ALA-ALA); Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 8 Years to 30 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: New York, New York

Conditions: Type 1 Diabetes
Interventions: Team Clinic Care, Standard Care; Other
Lead sponsor: Children's Hospital Los Angeles; Other
Eligibility: 10 Years to 17 Years
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Type1diabetes
Interventions: DIPPer Academy, Standard of Care; Behavioral · Other
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 3 Years to 65 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 2
States / cities: Kansas City, Kansas • Kansas City, Missouri

Conditions: Type 1 Diabetes (T1D), Pregnancy, Pre-Gestational Diabetes
Interventions: Automated insulin delivery (AID) system, Intravenous (IV) insulin; Device · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 3
States / cities: Los Angeles, California • San Diego, California • San Francisco, California

Conditions: Type 1 Diabetes
Interventions: Belatacept and Raptiva; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2016
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Type1diabetes, Type1 Diabetes Mellitus
Interventions: Type 1 Teamwork Program; Behavioral
Lead sponsor: Carelon Research; Other
Eligibility: Not listed
Enrollment: 158 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 2
States / cities: New Haven, Connecticut • Watertown, Massachusetts

Conditions: Diabetes Mellitus, Type 1
Interventions: occupation-based coaching; Behavioral
Lead sponsor: Creighton University; Other
Eligibility: 2 Years to 12 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Omaha, Nebraska

Search by objective public record fields.

Gene Expression Profiling in Type 1 Diabetes

A Trial Comparing the Efficacy of Insulin Degludec With Insulin Glargine on Glycaemic Control Using Continuous Glucose Monitoring in Patients With Type 1 Diabetes

High Risk Youth With Poorly-controlled Diabetes

Efficacy, Safety, and Tolerability Study of Sotagliflozin as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin Therapy

T1D Pregnancy & Me

Comparison of Glycemic Control Achieved With 2 Different Needles

Efficacy of Aliskiren in the Treatment of Diabetic Macular Edema

Effect of Closed Loop Glucose Control on Exercise-Associated Hypoglycemia

Outcomes and Cost Consequences of Using an Internet Co-Management Module to Improve the Quality of Type 1 Diabetes Care

Using SCOUT Noninvasive AGE Measurements to Forecast Diabetes Complications

Clinical Startup of the 670G Closed Loop Insulin Delivery System

Using Simplified Meal Boluses Versus Carbohydrate Counting in Adolescents With Hybrid Closed Loop Systems

Effect of Dietary Fat on Glycemic Control in Type 1 Diabetes

The Protégé Study - Clinical Trial of MGA031 in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus

SGLT2 Inhibitor Adjunctive Therapy to Closed Loop Control in Type 1 Diabetes Mellitus

Group Visits for High Risk Type 1 Diabetes (T1D)

Treatment of Tac-Expressing Cutaneous T-Cell Lymphoma (CTCL) and Adult T-Cell Leukemia (ATL) With Yttrium-90 Radiolabeled Anti-Tac

Safety and Pharmacokinetics (PK) of hOKT3g1 (Ala-Ala) in Type 1 Diabetes Mellitus (T1DM)

Team Clinic: Virtual Expansion of an Innovative Multi-Disciplinary Care Model for Adolescents and Young Adults With Type 1 Diabetes

Iterative Beta Testing of Videos for the DIPPer Academy

Automated Insulin for Management of Intrapartum Glycemia

Prevention of Autoimmune Destruction and Rejection of Human Pancreatic Islets Following Transplantation for Insulin Dependent Diabetes Mellitus

Type 1 Teamwork: A Tool for Parents of Adolescents With Type 1 Diabetes

Telehealth Family Coaching With Type 1 Diabetes